MedPath

HDL profiling in patients with deep vein thrombosis

Conditions
lipiden
trombose
venous thrombo-embolism
10014523
Registration Number
NL-OMON34805
Lead Sponsor
Academisch Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Cases: All patients with a first episode of a (objectified) deep vein thrombosis aged 18 years and older are eligible for participation.
Controls: Age and sex-matched individuals with complaints of the leg, in whom a DVT has been exluded by means of ultrasonography.

Exclusion Criteria

Those patienten with a previous venous thrombo-embolism, malignancy or other medical indication requiring long term anticoagulant treatment. Furthermore those patients with a history of cardiovascular disease or those using lipid lowering medication are not eligible for participation.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Protein profiling of HDL will be done using SELDI-TOF mass spectrometry.<br /><br>Additional laboratory testing will include determination of lipid spectrum<br /><br>(HDL-c, LDL-c, triglycerides, apo A1, apoB, total cholesterol), measurements of<br /><br>coagulation markers (aPTT, PT, protein S, activated protein C, F1+2, factor<br /><br>VIII, vWF), markers of fibrinolysis (ddimer) and inflammatory markers (CRP,<br /><br>Il-6, TNF-a, MCP, Leucocytes, SAA).</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Additional laboratory testing will include determination of lipid spectrum<br /><br>(HDL-c, LDL-c, triglycerides, apo A1, apoB, total cholesterol), measurements of<br /><br>coagulation markers (aPTT, PT, protein S, activated protein C, F1+2, factor<br /><br>VIII, vWF), markers of fibrinolysis (ddimer) and inflammatory markers (CRP,<br /><br>Il-6, TNF-a, MCP, Leucocytes, SAA).</p><br>
© Copyright 2025. All Rights Reserved by MedPath